$ABBV Recent News Yet again, Dow, S&P 500 notc
Post# of 72749
Posted On: 06/22/2014 2:20:05 PM
$ABBV Recent News
Yet again, Dow, S&P 500 notch new records 4:44 p.m. June 20, 2014 - Victor Reklaitis
Oracle slides on disappointing results; CarMax soars 4:16 p.m. June 20, 2014 - Ben Eisen
Shire boosts FTSE 100 to fourth day in black 12:37 p.m. June 20, 2014 - Sara Sjolin
European stocks lose steam after consumer data 12:09 p.m. June 20, 2014 - Sara Sjolin
AbbVie fails to woo Shire, but investors think someone can do it 11:10 a.m. June 20, 2014 - blogs.marketwatch.com
Newscast: A drug merger is on hold 10:04 a.m. June 20, 2014 - MarketWatch
Stock futures seesaw, but indexes eye weekly gains 8:04 a.m. June 20, 2014 - Carla Mozee
Newscast: A drug merger isn't happening right now 7:39 a.m. June 20, 2014 - MarketWatch
Shire rebuffs $46 billion takeover bid from AbbVie 3:29 a.m. June 20, 2014 - WSJ Staff
Rival to Gilead's pricey Sovaldi expected to hit market later this year 7:28 a.m. June 18, 2014 - blogs.marketwatch.com
E-Trade, Schwab up on HFT hearing; Tesla extends gains 3:53 p.m. June 17, 2014 - Ben Eisen
Microsoft, Amazon, Starbucks are stocks to watch 8:46 a.m. April 25, 2014 - Sue Chang
AbbVie shares rise after earnings top forecasts 8:10 a.m. April 25, 2014 - Ben Eisen
AbbVie shares rise 2.4% premarket on earnings 8:03 a.m. April 25, 2014 - Ben Eisen
Abbvie Q1 EPS tops forecast of $0.68 8:02 a.m. April 25, 2014 - Ben Eisen
AbbVie reaffirms 2014 adj EPS range of $3 to $3.10 8:00 a.m. April 25, 2014 - Ben Eisen
AbbVie Q1 sales rise to $4.56 bln vs $4.33 bln 7:59 a.m. April 25, 2014 - Ben Eisen
AbbVie Q1 EPS edges up to $0.61; Adjusted: $0.71 7:59 a.m. April 25, 2014 - Ben Eisen
AbbVie Q1 profit rises to $980 mln vs $968 mln 7:59 a.m. April 25, 2014 - Ben Eisen
I have no qualms about taking Gilead’s $84,000 drug 7:30 a.m. April 22, 2014 - Tim Mullaney
Dow, S&P 500 End at Records 7:33 p.m. June 20, 2014 - The Wall Street Journal Interactive Edition
Inversion Frenzy Rocks Drug Sector 7:28 p.m. June 20, 2014 - The Wall Street Journal Interactive Edition
Growth Stocks Kick Into Gear In Latest IBD 50 Screen 5:35 p.m. June 20, 2014 - Investors Business Daily
Just a Regular Day of Record Highs, No Big Deal 4:21 p.m. June 20, 2014 - TheStreet.com
European Investors Seek Safety 12:13 p.m. June 20, 2014 - The Wall Street Journal Interactive Edition
Stocks Rise as S&P 500 Extends Record High 12:07 p.m. June 20, 2014 - TheStreet.com
Achillion Could Win Idenix's Mystery Suitor: Analyst 11:44 a.m. June 20, 2014 - Investors Business Daily
Shire Rejects AbbVie's $46 Bil Tax-Inversion Attempt 10:41 a.m. June 20, 2014 - Investors Business Daily
AbbVie Needs More to Land Shire 10:20 a.m. June 20, 2014 - The Wall Street Journal Interactive Edition
AbbVie (ABBV) Is Today's Water-Logged And Getting Wetter Stock 9:52 a.m. June 20, 2014 - TheStreet.com
Shire Rejects $46B AbbVie Offer 9:40 a.m. June 20, 2014 - TheStreet.com
Stock Futures Trade Flat as Iraq Troubles Weigh 8:27 a.m. June 20, 2014 - TheStreet.com
Why Shire (SHPG) Stock Is Soaring This Morning 8:11 a.m. June 20, 2014 - TheStreet.com
AbbVie - Attempt To Acquire Shire Is Driven By Opportunistic Tax Synergies 7:34 a.m. June 20, 2014 - Seeking Alpha
More on AbbVie's pursuit of Shire 7:06 a.m. June 20, 2014 - Seeking Alpha
June 20 Premarket Briefing: 10 Things You Should Know 6:47 a.m. June 20, 2014 - TheStreet.com
European Stocks Lose Momentum but Remain Higher 6:37 a.m. June 20, 2014 - TheStreet.com
Wall Street Breakfast: Ukraine Tensions, Bank Settlements, Siemens Bid 6:33 a.m. June 20, 2014 - Seeking Alpha
Shire rejects AbbVie merger 2:31 a.m. June 20, 2014 - Seeking Alpha
Fire Up The Immuno-Oncology Powerhouses: John McCamant 5:39 p.m. June 19, 2014 - Seeking Alpha
NDA Resubmission, Accelerated Assessment of Marketing Application, and Esteemed Recognition - Analyst Notes on McKesson, AbbVie, Lilly, Zoetis and Salix 5:00 a.m. June 20, 2014 - PR Newswire - PRF
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 11:48 p.m. June 19, 2014 - PR Newswire - PRF
AbbVie Declares Quarterly Dividend 11:28 a.m. June 19, 2014 - PR Newswire - PRF
European Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C 2:00 a.m. June 17, 2014 - PR Newswire - PRF
Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis 7:30 a.m. June 16, 2014 - BusinessWire - BZX
U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C 3:34 p.m. June 13, 2014 - PR Newswire - PRF
Equity Coverage on Pharma Industry -- Research on AbbVie, AcelRx Pharma, Bristol-Myers Squibb, and GW Pharma 7:10 a.m. June 13, 2014 - PR Newswire - PRF
Expansions, New Leadership, Annual Award Winners, FDA Approvals, and Abstracts Presentations - Analyst Notes on AbbVie, Amgen, Regeneron Pharmaceuticals Inc, Valeant Pharmaceuticals and Lilly 6:40 a.m. June 12, 2014 - PR Newswire - PRF
AbbVie Presents Results from Large Global Study of Patient Attitudes and Adherence Across Six Chronic Inflammatory Diseases 2:00 a.m. June 11, 2014 - PR Newswire - PRF
AbbVie to Present at Goldman Sachs 35th Annual Global Healthcare Conference 8:00 a.m. June 10, 2014 - PR Newswire - PRF
AbbVie to Present at Jefferies 2014 Global Healthcare Conference 8:30 a.m. June 3, 2014 - PR Newswire - PRF
AbbVie Presents New Results from Studies of Investigational Oncology Compound ABT-199/GDC-0199 at the 2014 American Society of Clinical Oncology Annual Meeting 8:00 a.m. May 31, 2014 - PR Newswire - PRF
AbbVie Presents Results from Study of Investigational Compound in Patients with Glioblastoma at the American Society of Clinical Oncology's 50th Annual Meeting 8:00 a.m. May 30, 2014 - PR Newswire - PRF
Secondary Offering, Appointments, and Clinical Developments - Analyst Notes on HCA, Biogen Idec, WellPoint, AbbVie and Mylan 7:00 a.m. May 23, 2014 - PR Newswire - PRF
Study Results, Extension of Supply Agreements, Drug Designations, Senior Level Appointments, and Upcoming Events - Analyst Notes on InterMune, Actavis, Bristol-Myers, AbbVie and Illumina 8:30 a.m. May 22, 2014 - PR Newswire - PRF
Morning Analysis on Active Equities -- Research on AbbVie, Johnson Controls, DISH, and CEMEX 8:50 a.m. May 20, 2014 - PR Newswire - PRF
AbbVie to Present at 2014 UBS Global Healthcare Conference 8:00 a.m. May 20, 2014 - PR Newswire - PRF
AbbVie Announces Michael Severino, M.D. to Lead R&D Organization and Drive Continued Pipeline Advancement 12:00 p.m. May 15, 2014 - PR Newswire - PRF
Marketing Authorization Applications, Clinical Trial Results, Awards & Recognitions, and Resources Expansions - Analyst Notes on AbbVie, Medtronic, Abbott, Zimmer and Arena 8:40 a.m. May 15, 2014 - PR Newswire - PRF
Agreements, Earnings Releases, Senior-Level Retirements and Appointments, and Marketing Authorizations - Analyst Notes on Actavis, Jazz Pharmaceuticals, Bristol-Myers, Biogen Idec and AbbVie 7:00 a.m. May 14, 2014 - PR Newswire - PRF
Yet again, Dow, S&P 500 notch new records 4:44 p.m. June 20, 2014 - Victor Reklaitis
Oracle slides on disappointing results; CarMax soars 4:16 p.m. June 20, 2014 - Ben Eisen
Shire boosts FTSE 100 to fourth day in black 12:37 p.m. June 20, 2014 - Sara Sjolin
European stocks lose steam after consumer data 12:09 p.m. June 20, 2014 - Sara Sjolin
AbbVie fails to woo Shire, but investors think someone can do it 11:10 a.m. June 20, 2014 - blogs.marketwatch.com
Newscast: A drug merger is on hold 10:04 a.m. June 20, 2014 - MarketWatch
Stock futures seesaw, but indexes eye weekly gains 8:04 a.m. June 20, 2014 - Carla Mozee
Newscast: A drug merger isn't happening right now 7:39 a.m. June 20, 2014 - MarketWatch
Shire rebuffs $46 billion takeover bid from AbbVie 3:29 a.m. June 20, 2014 - WSJ Staff
Rival to Gilead's pricey Sovaldi expected to hit market later this year 7:28 a.m. June 18, 2014 - blogs.marketwatch.com
E-Trade, Schwab up on HFT hearing; Tesla extends gains 3:53 p.m. June 17, 2014 - Ben Eisen
Microsoft, Amazon, Starbucks are stocks to watch 8:46 a.m. April 25, 2014 - Sue Chang
AbbVie shares rise after earnings top forecasts 8:10 a.m. April 25, 2014 - Ben Eisen
AbbVie shares rise 2.4% premarket on earnings 8:03 a.m. April 25, 2014 - Ben Eisen
Abbvie Q1 EPS tops forecast of $0.68 8:02 a.m. April 25, 2014 - Ben Eisen
AbbVie reaffirms 2014 adj EPS range of $3 to $3.10 8:00 a.m. April 25, 2014 - Ben Eisen
AbbVie Q1 sales rise to $4.56 bln vs $4.33 bln 7:59 a.m. April 25, 2014 - Ben Eisen
AbbVie Q1 EPS edges up to $0.61; Adjusted: $0.71 7:59 a.m. April 25, 2014 - Ben Eisen
AbbVie Q1 profit rises to $980 mln vs $968 mln 7:59 a.m. April 25, 2014 - Ben Eisen
I have no qualms about taking Gilead’s $84,000 drug 7:30 a.m. April 22, 2014 - Tim Mullaney
Dow, S&P 500 End at Records 7:33 p.m. June 20, 2014 - The Wall Street Journal Interactive Edition
Inversion Frenzy Rocks Drug Sector 7:28 p.m. June 20, 2014 - The Wall Street Journal Interactive Edition
Growth Stocks Kick Into Gear In Latest IBD 50 Screen 5:35 p.m. June 20, 2014 - Investors Business Daily
Just a Regular Day of Record Highs, No Big Deal 4:21 p.m. June 20, 2014 - TheStreet.com
European Investors Seek Safety 12:13 p.m. June 20, 2014 - The Wall Street Journal Interactive Edition
Stocks Rise as S&P 500 Extends Record High 12:07 p.m. June 20, 2014 - TheStreet.com
Achillion Could Win Idenix's Mystery Suitor: Analyst 11:44 a.m. June 20, 2014 - Investors Business Daily
Shire Rejects AbbVie's $46 Bil Tax-Inversion Attempt 10:41 a.m. June 20, 2014 - Investors Business Daily
AbbVie Needs More to Land Shire 10:20 a.m. June 20, 2014 - The Wall Street Journal Interactive Edition
AbbVie (ABBV) Is Today's Water-Logged And Getting Wetter Stock 9:52 a.m. June 20, 2014 - TheStreet.com
Shire Rejects $46B AbbVie Offer 9:40 a.m. June 20, 2014 - TheStreet.com
Stock Futures Trade Flat as Iraq Troubles Weigh 8:27 a.m. June 20, 2014 - TheStreet.com
Why Shire (SHPG) Stock Is Soaring This Morning 8:11 a.m. June 20, 2014 - TheStreet.com
AbbVie - Attempt To Acquire Shire Is Driven By Opportunistic Tax Synergies 7:34 a.m. June 20, 2014 - Seeking Alpha
More on AbbVie's pursuit of Shire 7:06 a.m. June 20, 2014 - Seeking Alpha
June 20 Premarket Briefing: 10 Things You Should Know 6:47 a.m. June 20, 2014 - TheStreet.com
European Stocks Lose Momentum but Remain Higher 6:37 a.m. June 20, 2014 - TheStreet.com
Wall Street Breakfast: Ukraine Tensions, Bank Settlements, Siemens Bid 6:33 a.m. June 20, 2014 - Seeking Alpha
Shire rejects AbbVie merger 2:31 a.m. June 20, 2014 - Seeking Alpha
Fire Up The Immuno-Oncology Powerhouses: John McCamant 5:39 p.m. June 19, 2014 - Seeking Alpha
NDA Resubmission, Accelerated Assessment of Marketing Application, and Esteemed Recognition - Analyst Notes on McKesson, AbbVie, Lilly, Zoetis and Salix 5:00 a.m. June 20, 2014 - PR Newswire - PRF
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 11:48 p.m. June 19, 2014 - PR Newswire - PRF
AbbVie Declares Quarterly Dividend 11:28 a.m. June 19, 2014 - PR Newswire - PRF
European Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C 2:00 a.m. June 17, 2014 - PR Newswire - PRF
Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis 7:30 a.m. June 16, 2014 - BusinessWire - BZX
U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C 3:34 p.m. June 13, 2014 - PR Newswire - PRF
Equity Coverage on Pharma Industry -- Research on AbbVie, AcelRx Pharma, Bristol-Myers Squibb, and GW Pharma 7:10 a.m. June 13, 2014 - PR Newswire - PRF
Expansions, New Leadership, Annual Award Winners, FDA Approvals, and Abstracts Presentations - Analyst Notes on AbbVie, Amgen, Regeneron Pharmaceuticals Inc, Valeant Pharmaceuticals and Lilly 6:40 a.m. June 12, 2014 - PR Newswire - PRF
AbbVie Presents Results from Large Global Study of Patient Attitudes and Adherence Across Six Chronic Inflammatory Diseases 2:00 a.m. June 11, 2014 - PR Newswire - PRF
AbbVie to Present at Goldman Sachs 35th Annual Global Healthcare Conference 8:00 a.m. June 10, 2014 - PR Newswire - PRF
AbbVie to Present at Jefferies 2014 Global Healthcare Conference 8:30 a.m. June 3, 2014 - PR Newswire - PRF
AbbVie Presents New Results from Studies of Investigational Oncology Compound ABT-199/GDC-0199 at the 2014 American Society of Clinical Oncology Annual Meeting 8:00 a.m. May 31, 2014 - PR Newswire - PRF
AbbVie Presents Results from Study of Investigational Compound in Patients with Glioblastoma at the American Society of Clinical Oncology's 50th Annual Meeting 8:00 a.m. May 30, 2014 - PR Newswire - PRF
Secondary Offering, Appointments, and Clinical Developments - Analyst Notes on HCA, Biogen Idec, WellPoint, AbbVie and Mylan 7:00 a.m. May 23, 2014 - PR Newswire - PRF
Study Results, Extension of Supply Agreements, Drug Designations, Senior Level Appointments, and Upcoming Events - Analyst Notes on InterMune, Actavis, Bristol-Myers, AbbVie and Illumina 8:30 a.m. May 22, 2014 - PR Newswire - PRF
Morning Analysis on Active Equities -- Research on AbbVie, Johnson Controls, DISH, and CEMEX 8:50 a.m. May 20, 2014 - PR Newswire - PRF
AbbVie to Present at 2014 UBS Global Healthcare Conference 8:00 a.m. May 20, 2014 - PR Newswire - PRF
AbbVie Announces Michael Severino, M.D. to Lead R&D Organization and Drive Continued Pipeline Advancement 12:00 p.m. May 15, 2014 - PR Newswire - PRF
Marketing Authorization Applications, Clinical Trial Results, Awards & Recognitions, and Resources Expansions - Analyst Notes on AbbVie, Medtronic, Abbott, Zimmer and Arena 8:40 a.m. May 15, 2014 - PR Newswire - PRF
Agreements, Earnings Releases, Senior-Level Retirements and Appointments, and Marketing Authorizations - Analyst Notes on Actavis, Jazz Pharmaceuticals, Bristol-Myers, Biogen Idec and AbbVie 7:00 a.m. May 14, 2014 - PR Newswire - PRF
(0)
(0)